Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
Breast Cancer Research, Volume 11, No. 6, Article R90, Year 2009
Notification
URL copied to clipboard!
Description
Introduction: Candidacy for anti-HER2 adjuvant therapy in breast cancer is assessed using tumour HER2 status but recently it has been proposed that the transcription factors AP-2α and YY1 may cause Her2 protein overexpression independently of gene amplification.Methods: We characterised AP-2α/β, AP-2α and YY1 with HER2 gene and protein expression, other relevant biomarkers, and clinical outcome using tissue microarrays (TMAs) and immunohistochemistry in a large (n = 1,176) clinically annotated series of early stage operable breast cancer. The associations and prognostic independence of AP-2 and YY1 was assessed in all patients and an oestrogen receptor negative subgroup.Results: Nuclear expression of AP-2α/β, AP-2α and YY1 was detected in 23%, 44% and 33% of cases respectively. AP-2α/β significantly correlated with YY1 and both markers were increased in luminal oestrogen receptor (ER) positive tumours of small size and low grade but only AP-2α/β correlated with good prognosis breast cancer specific survival and disease free interval (BCSS and DFI). These characteristics were lost in oestrogen receptor negative patients. AP-2α also correlated with luminal-type tumours but not with YY1 expression or good prognosis. AP-2α and YY1 showed a significant correlation with Her2 protein expression and in addition, YY1 correlated with HER2 gene expression. Discordant HER2 gene and protein expression was identified in six cases (0.71% of the study group) with four of these showing AP-2α but absence of AP-2α/β and YY1 expression.Conclusions: AP-2α/β and YY1 are markers of good prognosis principally due to their association with oestrogen receptor but are not independent predictors. Discordant HER2 protein/gene expression is a rare event that is not always explained by the actions of AP-2 and YY1. © 2009 Powe et al.; licensee BioMed Central Ltd.
Authors & Co-Authors
Powe, Desmond George
United Kingdom, Nottingham
Queen's Medical Centre
Akhtar, Gulfareen
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Habashy, Hany Onsy
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Egypt, Mansoura
Faculty of Medicine
Abdel-Fatah, Tarek M.A.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Rakha, Emad A.
United Kingdom, Nottingham
Queen's Medical Centre
Green, Andew R.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Ellis, Ian O.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Statistics
Citations: 51
Authors: 7
Affiliations: 3
Identifiers
Doi:
10.1186/bcr2461
ISSN:
14655411
e-ISSN:
1465542X
Research Areas
Cancer
Genetics And Genomics